Methods and pharmacological compositions for wound healing

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and can be used to induce or accelerate healing of skin damages or skin wounds. That is ensured by introduction of an agent used to simulate expression and/ or activity of at least one PKC isoform in dermal cells colonising a damaged skin or a skin wound area. It is combined with introduction of at least one agent specified from insulin, growth factor, adipokin, PKC RACK and GW9662. Therefore, appropriate pharmaceutical compositions for local application are used.

EFFECT: inventions ensure fast wound closure, accelerate scarring due to synergetic effect of said products in combination.

39 cl, 5 tbl, 27 ex, 43 dwg

 

The text descriptions are given in facsimile form.

1. Method of inducing or accelerating the healing process of a damaged skin or skin wound, comprising the modulation of expression and/or activity of at least one isoform of the RCC in colonizing the damaged skin or area of skin wounds dermal cells and the introduction of a therapeutically effective amount of at least one additional means selected from the group consisting of insulin, growth factor, adipokine, RKS RACK and GW9662 in order to thereby accelerate the healing process of a damaged skin or skin wound.

2. The method according to claim 1, where these dermal cells are fibroblasts or keratinocytes.

3. The method according to claim 2, where this isoform RKS selected from the group consisting of α, β, δ, PKCε, PKCη and ζ.

4. The method according to claim 2, where the specified growth factor selected from the group consisting of IL-6, KFG and TNFα, as specified adipokine is adipsin or adiponectin.

5. The method according to claim 1, where the expression and/or activity specified isoforms RKS inhibit.

6. The way is about to claim 5, where inhibition of this isoform CSWs reached by means of small molecules interfering RNA (siRNA) or by infetsirovaniya these dermal cells adenoviral design with dominant-negative CSWs.

7. The method according to claim 1, where the expression and/or activity specified isoforms RKS trigger.

8. The method according to claim 7, where the activation of this isoform CSWs reached by means of investirovanie these dermal cells adenoviral construct with isoform RKS wild-type.

9. The method according to claim 6, where this isoform RKS is a α, a specified additional tool is insulin, TNFα, adipsin or δ RACK.

10. The method according to claim 6, where this isoform RKS is a β, and this additional tool is insulin, KGF, IL-6 or GW9662.

11. The method according to claim 6, where this isoform RKS is a ζ, and this additional tool is insulin, IL-6, TNFα, KGF or adiponectin.

12. The method of claim 8, where this isoform RKS is a δ, and said additional means is adipsin.

13. The method according to claim 1, including an introduction to these dermal cells therapeutically effective amounts of substances capable of modulating the expression and/or activity of at least one pointed to by the y isoform of the RCC and the specified additional funds.

14. The method according to item 13, where the specified substance is an inhibitor α, preferably N-monitorowania peptide pseudoobscura α.

15. The method according to 14, where this additional tool is insulin.

16. The method according to clause 15, which includes the introduction in these dermal cells therapeutically effective amounts of N-monitorowania peptide pseudoobscura α and insulin.

17. The method according to item 13, where the specified substance is an inhibitor β; inhibitor η, preferably N-monitorowania peptide pseudoobscura η or inhibitor ζ, preferably N-monitorowania peptide pseudoobscura ζ.

18. The method according to item 13, where the specified substance is an activator δ, preferably insulin or δ RACK.

19. The method according to any one of claims 1 to 18, where the specified skin wound is selected from the group consisting of ulcers, wounds associated with diabetes, burns, sunburn, chronic skin wounds, wounds with epidermolysis-bullosa, a skin-naravnoy wound, a psoriasis wound, wounds of the skin of an animal diabetic wound the animal, lacerations, wounds, surgical incisions and postoperative adhesive wound.

20. The method according to claim 19, where this plague is selected from the group consisting of diabetic ulcers, decubitus, venous ulcers and ulcers associated with HIV.

21. The method according to any ISP-18, where the specified substance and additional means are contained in a pharmaceutical carrier adapted for topical application.

22. The method according to item 21, where the specified substance and additional means are contained in a pharmaceutical carrier, presented in the form of an aqueous solution, gel, cream, paste, lotion, spray, suspension, powder, colloidal solution, balm and ointments.

23. The method according to item 22, where the specified substance and additional means are contained in a pharmaceutical carrier, including a solid Foundation.

24. Method of inducing or accelerating the healing process of a damaged skin or skin wound, comprising the modulation of expression and/or activity in the dermal cells colonizing the damaged skin or area of skin wounds two isoforms of the RCC selected from the group consisting of α, β, δ, ε, η and ζ, thus inducyruya or accelerating a healing process of a damaged skin or skin wound.

25. The method according to paragraph 24, where these dermal cells are fibroblasts or keratinocytes.

26. The method according A.25, where expression and/or activity of at least one of these two isoforms RKS ingibirovany molecule, a small interfering RNA (siRNA) or infection of these dermal cells adenoviral design with dominant-negative CSWs.

27. The method according to claim 2, where expression and/or activity of at least one of these two isoforms RKS activated by investirovanie these dermal cells adenoviral construct with isoform RKS wild-type.

28. The method according to p or 27, where α ingibirovany and δ activated.

29. The method according to p, where α, and δ ingibirovany.

30. The method according to paragraph 24, where the specified skin wound is selected from the group consisting of ulcers, wounds associated with diabetes, burns, sunburn, chronic skin wounds, wounds with epidermolysis-bullosa, a skin-naravnoy wound, a psoriasis wound, wounds of the skin of an animal diabetic wound the animal, lacerations, wounds, surgical incisions and postoperative adhesive wound.

31. The method according to item 30, where this plague is selected from the group consisting of diabetic ulcers, decubitus, venous ulcers and ulcers associated with HIV.

32. Pharmaceutical composition for topical application for induction or acceleration of the healing process of a damaged skin or skin wound, containing a therapeutically effective amount of a substance capable of modulating the expression and/or activity of at least one isoform of the RCC and at least one additional agent selected from the group consisting of insulin, growth factor, adipokine, RKS RACK and GW9662, and a pharmaceutically acceptable carrier.

33. Pharmaceutical to the position p, where this isoform RKS selected from the group consisting of α, β, δ, PKCε, PKCη and ζ.

34. The pharmaceutical composition according p, where the specified growth factor selected from the group consisting of IL-6, KFG and TNFα, as specified adipokine is adipsin or adiponectin.

35. The pharmaceutical composition according p, where the specified substance is an inhibitor of the isoform of the RCC.

36. The pharmaceutical composition according p, where the specified inhibitor isoforms RKS is an inhibitor α, preferably N-monitorowania peptide pseudoobscura α.

37. The pharmaceutical composition according p, where the specified inhibitor isoforms RKS is an inhibitor η, preferably N-monitorowania peptide pseudoobscura η; or inhibitor ζ, preferably N-monitorowania peptide pseudoobscura ζ.

38. The pharmaceutical composition according p, where the specified inhibitor isoforms RKS is an inhibitor α N-monitorowania peptide pseudoobscura α, and this additional tool is insulin.

39. The pharmaceutical composition according p, where the specified substance is an activator isoforms RKS, preferably the activator σ, such as insulin or σ RACK.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to combustiology and surgery. The technique involves preliminary abrasion of a wound and application of fibroblasts on the wound surface. The fibroblasts are distributed in a gel mixture. Said gel mixture contains a serum-free nutrient medium and methylcellulose in amount 1.0 - 3.0 wt %.

EFFECT: method prolongs viability of the cells applied on the wound, prevents occurrence of allergic reaction.

5 cl, 3 ex, 1 tbl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves introduction to a mammal of therapeutically effective amount of a compound exhibiting properties of antagonist of A2B receptor of the following formula: , where R1 and R2 independently represent lower alkyl, R3 represents hydrogen, X represents pyrazolene, Y represents lower alkylene, and Z represents phenyl or pyridyl which can be substituted with trifluoromethyl. Besides the invention covers a pharmaceutical composition.

EFFECT: accelerated wound healing in a mammal.

7 cl, 6 dwg, 2 tbl, 22 ex

FIELD: medicine.

SUBSTANCE: invention presents a composition for local healing of septic wounds and trophic ulcers, including application of the medicines appropriate to the sensitivity of microorganisms in a wound, differing that it contains an antiseptic, high-purity beet pectin and water with all of components taken in a certain mass ratio.

EFFECT: invention provides intensification of antiseptic properties that is ensured by application of high-purity beet pectin which provides cleaning of a wound or a trophic ulcer in a relatively short time owing to bactericidal action; beet pectin provides accelerated regeneration of wound surface; the offered composition is absolutely nontoxic that eliminates the collateral action, besides introduction of pectin reduces a dosage of the antiseptic, and as a whole accelerates medical and social rehabilitation of the patient.

1 ex, 1 tbl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention relates to wound-healing medication, which includes active substance - nanoparticles, containing 98-99% of iron oxide-hydroxide (IOH) and oxides of silicon, aluminium, calcium, isolated from underground waters on deironing stations, polyvinyl alcohol and water. Invention also relates to method of obtaining wound-healing medication, which includes mixing of components and processing of suspension with ultrasound.

EFFECT: invention allows to obtain medication possessing wound-healing and bactericidal properties of prolonged action.

2 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a wound healing agent. The wound healing gel balm containing dihydroquercetin, medicinal glycerine, linseed or cedar oil, aqueous chitosan gel taken in a certain ratio of components.

EFFECT: wound healing and antiinflammatory gel balm.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to ointment for treating burn diseases. The ointment for treating burn diseases, containing as an active substance, dry albumin and ethanolic propolis extract, and as an ointment base, salve base, penthol and purified water in a certain ratio of components.

EFFECT: ointment exhibits reparative, antiinflammatory, dehydrating, necrolitic and antimicrobic action and is effective for treating burn diseases.

5 ex

FIELD: medicine.

SUBSTANCE: invention refers to development of technology of an external medical product that expresses wound-healing, antiinflammatory, antiseptic properties and can be used in medical practice for treating skin diseases (burns, wounds, cuts, inflammations, suppurations etc.) and for preventive skin protection. The technology involves the following stages: preparation of an aqueous solution of lanthanum nitrate, dissolution of the product in triethylene glycol or tetraethylene glycol, addition of glycerine and, if necessary, ethyl alcohol, preparation of an alkaline solution of ethyl carbitol or an alkaline solution of ethyl alcohol, alkalization of the product to pH=6.5-7.4.

EFFECT: new technology enables the commercial process without complex hardware and ensures a high-yield and stable end product.

32 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine and biology, particularly biological preparations, and can find application in treatment of wounds, burns, tumours and correction of metabolic processes. The problem whereat the declared invention aims, is improving the clinical effectiveness for wide spectrum of inflammatory diseases, particularly, reduced time for achievement of medical effect and/or prolongation of remission periods and increased resistance of the patients to infections. The task in view is solved by that a biologically active preparation represents a suspension of particles of powdered copper, iron and zinc made of the alloy exposed to the plasma flux at temperature 5000-6000°K, in 0.9% NaCl solution in the weight ratio Cu:Fe:Zn=60:15:25, dispersion of particles 180-220 nm and concentration of the suspension equal of 10 mg/ml.

EFFECT: improved bactericidal effect of the preparation, reduction of pyoinflammatory processes in short terms and early activation of the patients.

1 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry and concerns pharmaceutical composition for prevention and treatment of diseases and disease states connected with metabolic pathways of cycloxygenase-2 (CG-2) and 5-lipooxygenase (5-LO), which contains mixture of extract obtained from Scutellariae and enriched with flavonoids with free B-ring, which include baicalein, and extract obtained from Acacia and enriched with flavans, which include catechine and epicatechine. Claimed invention also relates to method of body weight loss and control over glucose level in blood. Methods by claimed invention include introduction to person, who needs it, of efficient amount of composition by claimed invention together with pharmaceutically acceptable carrier. Claimed invention mainly relates to prevention and treatment of diseases and states connected with metabolic pathways of cycloxygenase-2 (CG-2) and 5-lipooxygenase (5-LO), including, but not confining to it, stopping discomfort and pain in joints, induced by such states as osteoarthritis, rheumatoid arthritis and other injuries caused by overload.

EFFECT: composition possesses high efficiency.

35 cl, 22 ex, 15 tbl

FIELD: medicine.

SUBSTANCE: invention concerns chemical-pharmaceutical industry, namely production of gel for treatment, prevention of formation of keloid and hypertrophic skin cicatrices. As biologically active components, said gel contains liposome suspension 18.0-20.0% with their membrane formed by phospholipids, lipids of animal and vegetable origin with included chloroform herbal extract, and in internal aqueous volume of lipid vesicles, there are extracts of foetal placenta, umbilical cords of pigs and mineral water Narzan. A gelling composition consists of ammonium salt of lightly cross-linked copolymer of acrylic acid, polyallyl esters of pentaerythrite, glycerine, triethanolamine, methyl and propyl esters of paraoxybenzoic acids, an aromatiser and water.

EFFECT: there is also offered method for gel making.

2 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry. A method for preparing a pharmaceutical composition containing crystalline insulin AspB28 and dissolved insulin AspB28, protamine, Zn2+, an isotonic agent and a phenol compound by preparing an acid solution containing insulin AspB28, and an alkaline solution containing a substance which at physiological pH reacts as a buffer; at least one solution contains the phenol compound, mixed acid and alkaline solutions; the mixture is settled to form the pharmaceutical composition containing a phase with dissolved insulin AspB28 and a phase with crystallne insulin AspB28 to be added to the other phenol compound.

EFFECT: preparation of the pharmaceutical composition containing crystalline insulin AspB28 and dissolved insulin AspB28.

3 cl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to chemistry of polymers, biochemistry and medicine, and specifically to a method of preparing glucose-sensitive polymer hydrogels used as carriers for controlled secretion of insulin. The glucose-sensitive polymer hydrogels are obtained from reaction of a glucose derivative with concanavalin A. The reaction is carried out through copolymerisation in an aqueous solution under the effect of a redox initiator of 0.1-2.0 wt % N-(2-D-glucose)acrylamide, 1-5 wt % acrylamide and 0.01-0.075 wt % N,N-methylenebisacrylamide in the presence of 5-20 wt % concanavalin A.

EFFECT: obtaining polymer hydrogels which can be insulin carriers, with no other components of the hydrogel being released into the surrounding medium.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to endocrinology, and can be used for treating type 2 diabetes that is ensured by introduction of effective amount of compound Cysteamine or its salts combined with metformin or insulin.

EFFECT: invention allows improving clinical effectiveness due to higher expression of glucose transporter and higher adiponectin level that increases insulin sensitivity.

7 tbl, 4 ex, 10 dwg

FIELD: medicine; surgery.

SUBSTANCE: lumen of a gall bladder is opened, concrements are removed, a gall bladder is drained. Sanation of a gall bladder cavity is carried out in the early postoperative period using a solution of the following structure: Furacilinum of 0.02% - 2 mg, Chymotrypsin - 0.2% - 20 mg, Hidrocortizonum of 0.5% - 50 mg, water - the rest up to 10 ml.

EFFECT: fast restoration of gall bladder functions, elimination of risk factors of cholecystolithiasis relapse development.

1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine and claims therapeutic material and therapeutic media based on it for purulo-necrotic wound treatment, as well as method of obtaining therapeutic material. Material includes activated textile carrier with trypsin, insulin and lysocim immobilised in it.

EFFECT: significant reduction of wound surface cleaning time, accelerated healing.

17 cl, 2 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to ophthalmology, and covers therapy of postcontusional damaged retina associated with visual dysfunctions. The therapy includes vitamin B complex combined with instilled nonsteroid antiinflammatory eye drops 3-5 times a day in dosage 2 drops within 7-10 days from the first day and cornea regeneration stimulators dosed 2 drops 3-4 times a day within 3-5 days, and oral day tranquilizers dosed 5-10 mg 1-2 times a day within 7-10 days. Besides, haemostatic agents are injected intramuscularly in dosage 1 ml once a day within 3-5 days as combined with daily intravenous droplet introduction of a composition including Panangin solution 20.0 ml, 5% Glucose solution 200.0 ml and Insulin 4 UN once a day within 3-5 days.

EFFECT: method allows for more apparent therapeutic effect including short-term higher visual acuity and preserved colour sense with extended visual field.

5 cl, 2 ex

Insulin derivatives // 2352581

FIELD: medicine.

SUBSTANCE: invention concerns derivatives of a misinformation (B30) human insulin which have lateral a chain, attached to ε-amino group of the rest of the lysine which is present at the B-chain of initial insulin where this lateral the chain has the general formula: -W-X-Y-Z where W, X, Y and Z are such as it is defined in the description.

EFFECT: increased efficiency.

15 cl, 4 tbl, 37 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, in particular to endocrinology, and relate to treatment of 2nd type diabetes complicated by a polyneuropathy. For this purpose against basic complex therapy of diabetes in addition tylorone is entered on 250 mg/days into 1st and 2nd days of treatment. Further tylorone is administered on 125 mg in two days on the third. On course of treatment the preparation dose makes not less than 2500 mg.

EFFECT: for the first time the developed regimen of the chosen immunomodulator administration for the given contingent of patients allows to raise efficiency of treatment.

2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to medicinal agents and concerns pharmaceutical formulation for nasal absorption containing biologically active acidic polypeptide with isoelectric point 7 and lower; carrier which is water-insoluble or weak-soluble and contains particles of average size 100 mcm and less; and adjuvant for dispersion and consolidation of polypeptide on carrier surface, which is water-insoluble or weak-soluble, where average size of particle contained in specified adjuvant is lower than average size of carrier and is within the range 1 mcm to 20 mcm.

EFFECT: improved biological acceptability of biologically active polypeptide.

6 cl, 4 dwg, 11 tbl, 47 ex

FIELD: medicine, endocrinology, pharmacology.

SUBSTANCE: invention describes a method for preparing the insulin preparation. Method involves adding insulin to 1-50% aqueous solution of polyethylene oxide of molecular mass 0.4-40 kDa irradiated preliminary by ionizing radiation in the dose 1.0-5.0 Mrad to its final concentration 1-10 mg/ml and in the ratio polyethylene oxide : insulin = (1-500):1. Prepared mixture is stirred up to preparing a homogenous, clear or slightly opalescent solution. Method provides simplifying the process for preparing the insulin preparation and to enhance its therapeutic activity.

EFFECT: improved preparing method.

2 cl, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention is related to medicine and concerns applications of lactic osteopontine for decrease of bacterial plaque growth on the enamel, and dental compositions containing lactic osteopontine.

EFFECT: invention ensures lactic osteopontine to inhibit bacterial adhesion to a surface of tooth.

7 cl, 1 ex, 1 dwg, 2 tbl

Up!